The New York State Department of Health today announced that it has authorized five additional registered organizations (ROs) to manufacture and dispense medical marijuana in New York State, an initiative aimed at improving patient access and the geographic distribution of dispensing facilities across the state.
The new ROs are: Citiva Medical; Fiorello Pharmaceuticals; New York Canna (d/b/a Terradiol New York); PalliaTech NY and Valley Agriceuticals. They join the following five ROs, which have been operating since the program’s launch in January 2016 and have been re-registered for another two years: MedMen, formerly known as Bloomfield Industries; Columbia Care; Etain; PharmaCann; and Vireo Health of New York.
“The New York State Department of Health is committed to growing the state’s Medical Marijuana Program responsibly,” said New York State Department of Health Commissioner Dr. Howard Zucker. “The addition of these registered organizations will make it easier for patients across the state to obtain medical marijuana, improve the affordability of medical marijuana products through the introduction of new competition, and increase the variety of medical marijuana products available to patients.”
The new ROs will operate in the following locations:
- Citiva Medical will manufacture in Orange County and have dispensing facilities in Dutchess, Chemung, Kings and Richmond Counties.
- Fiorello Pharmaceuticals will manufacture in Schenectady County and have dispensing facilities in Monroe, Saratoga, New York and Nassau Counties.
- New York Canna (d/b/a Terradiol New York) will manufacture in OnondagaCounty and have dispensing facilities in Erie, Orange, Queens and Suffolk Counties.
- PalliaTech NY will manufacture in Ulster County and have dispensing facilities in Nassau, Orange, Queens, and Clinton Counties.
- Valley Agriceuticals will manufacture in Orange County and have dispensing facilities in Kings, Oneida, Suffolk, and Dutchess Counties.
Other recent enhancements to New York State’s Medical Marijuana Program include adding chronic pain as a qualifying condition, permitting home delivery, empowering nurse practitioners and physician assistants to certify patients, and publishing a list of registered practitioners who have consented to be listed publicly.
As of August 1, 2017, there are 25,736 certified patients and 1,139 registered practitioners participating in the program. The number of certified patients has increased by 10,744 (72 percent) since the addition of chronic pain in late March.
Integrating five additional registered organizations into the industry utilizing a phased-in approach was a recommendation of the Department’s two-year report on the Medical Use of Marijuana Under the Compassionate Care Act.